Review
Open access
Jul 2026
CAR-T and TIL therapies in solid tumors: barriers, clinical lessons, and convergent solutions
The approval of lifileucel in 2024 marked an important milestone in oncology as the first cellular therapy authorized for a solid tumor and a review of the biological obstacles, emerging convergence strategies, and translational frameworks including biomarker-guided patient selection that define this new area.
Duc-Hiep Bach, Van T. Hoang, T. Pham et al.
· Cancer Cell International · 2 citations